{"product_id":"amphastar-swot-analysis","title":"Amphastar Pharmaceuticals SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAmphastar Pharmaceuticals shows strengths in niche inhalation and injectable products and a resilient generics revenue base, but faces margin pressure from pricing dynamics, regulatory scrutiny, and patent expiration risks; operational execution and pipeline diversification will be key. Discover the full SWOT analysis for detailed, editable insights, financial context, and strategic recommendations to guide investing or planning—available instantly for purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertically Integrated Manufacturing Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmphastar controls key supply links via Armstrong Pharmaceuticals and API plants in China and France, producing over 60% of APIs in-house as of 2025, which cut COGS volatility and improved gross margin to 37.4% in FY2024.\u003c\/p\u003e\n\u003cp\u003eVertical integration limits third-party disruption risk for complex injectables and inhalation products, supporting 98% on-time production and steady revenue from specialty lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Position in OTC Inhalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs owner of the only FDA‑approved OTC epinephrine inhaler, Primatene Mist, Amphastar holds a unique, high‑barrier market position that drove $112m in product sales in 2024 and supported ~20% of company revenue; strong consumer brand recognition and no direct OTC generic competitors sustain a steady retail revenue stream. Primatene’s approval shows Amphastar’s regulatory expertise in complex drug‑device combos, easing future product approvals and M\u0026amp;A leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Integration of Baqsimi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe 2020 acquisition and integration of Baqsimi (nasal glucagon) from Eli Lilly boosted Amphastar’s portfolio and emergency glucose market position, adding roughly $110–130M in annual revenue by 2024 and contributing ~18% of 2024 product sales.\u003c\/p\u003e\n\u003cp\u003eIntegration cut launch-to-scale time, preserved supply continuity, and by 2025 Amphastar held an estimated 40–45% share of the nasal glucagon market versus competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Expertise in Complex Generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmphastar focuses on complex generics—injectables, inhalation, and intranasal systems—requiring advanced engineering, which creates a durable competitive moat and supports pricing stability versus simple oral generics.\u003c\/p\u003e\n\u003cp\u003eThis high-barrier focus drove 2024 product mix strength: ~65% of revenue from specialty injectables and devices, helping gross margins remain near 38% in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty products: injectables, inhalation, intranasal\u003c\/li\u003e\n\u003cli\u003e2024: ~65% revenue from specialty lines\u003c\/li\u003e\n\u003cli\u003eFY2024 gross margin ~38%\u003c\/li\u003e\n\u003cli\u003eHigher pricing sustainability, lower competition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisciplined Financial Profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy end-2025 Amphastar Pharmaceuticals reported a strong balance sheet with roughly $420m cash and short-term investments and free cash flow of about $95m in FY2025, enabling funding for R\u0026amp;D and selective acquisitions without heavy debt or equity raises.\u003c\/p\u003e\n\u003cp\u003eThis self-funding stance lets Amphastar target higher-margin biosimilar projects while avoiding volatile debt markets and dilution, a clear edge among mid-tier biopharma peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$420m cash \u0026amp; short-term investments (2025)\u003c\/li\u003e\n\u003cli\u003e$95m free cash flow (FY2025)\u003c\/li\u003e\n\u003cli\u003eLow reliance on debt\/equity financing\u003c\/li\u003e\n\u003cli\u003eFocus on high-value biosimilars\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmphastar’s vertical integration boosts margins, specialty injectables drive strong cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmphastar’s vertical integration (60%+ API in‑house, plants in China\/France) raised FY2024 gross margin to 37.4% and cut COGS volatility; specialty injectables\/inhalation made ~65% revenue in 2024. Primatene Mist drove $112m (2024); Baqsimi added $110–130m (2024) and ~40–45% nasal glucagon share by 2025. Cash ~$420m, FCF ~$95m (FY2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin FY2024\u003c\/td\u003e\n\u003ctd\u003e37.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty mix 2024\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimatene sales 2024\u003c\/td\u003e\n\u003ctd\u003e$112m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBaqsimi sales 2024\u003c\/td\u003e\n\u003ctd\u003e$110–130m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (2025)\u003c\/td\u003e\n\u003ctd\u003e$420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF FY2025\u003c\/td\u003e\n\u003ctd\u003e$95m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Amphastar Pharmaceuticals, highlighting its manufacturing and injectable expertise, regulatory and product-concentration vulnerabilities, growth opportunities in biosimilars and contract manufacturing, and competitive, legal, and pricing pressures that may impact future performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix for Amphastar Pharmaceuticals to quickly align strategic priorities and communicate competitive risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Revenue Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 40% of Amphastar Pharmaceuticals’ 2024 product revenue came from Primatene Mist and Baqsimi, so regulatory changes, safety alerts, or new generics could hit overall revenue sharply.\u003c\/p\u003e\n\u003cp\u003eAny FDA action or competitor launch against either brand could cut margins and EPS disproportionately, given limited product breadth.\u003c\/p\u003e\n\u003cp\u003eDiversifying into more high-volume SKUs remains a top management challenge; current R\u0026amp;D and M\u0026amp;A plans aim to reduce concentration but show slow progress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubstantial Research and Development Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmphastar spends a material share of revenue on R\u0026amp;D—about 11% of 2024 net sales ($~60m of $545m)—to advance complex generics and biosimilars, which supports long-term growth but reduces near-term profits.\u003c\/p\u003e\n\u003cp\u003eThose high, multi-year costs compressed 2024 adjusted operating margin to roughly 12%, and failed or delayed approvals would magnify margin pressure and capital draw.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistory of Regulatory Delays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpamphastar has a history of fda setbacks including multiple complete response letters and approval delays inhaled insulin nda experienced review extension timelines costs. these regulatory hurdles drove an estimated in remediation re-filing expenses fy2022 caused missed revenue from delayed market launches. dependence on timely approvals makes projected growth volatile analysts modeled range eps tied to timing.\u003e\n\u003c\/pamphastar\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Raw Material Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpdespite its vertical integration amphastar pharmaceuticals still depends on specialized chemicals and sterile packaging that face global price swings occasional shortages which in contributed to a percentage-point gross-margin pressure versus fy2023.\u003e\n\u003cpmanaging these input-costs is a constant operational hurdle for complex injectable manufacturing because rapid raw-material cost rises cannot always be passed to customers due contract terms and competitive pricing.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e2024: raw-material inflation cut GM by ~1.8 ppt\u003c\/li\u003e\n\u003cli\u003eKey risks: specialized chemicals, sterile vials, cold-chain components\u003c\/li\u003e\n\u003cli\u003eMitigation: supplier diversification, longer-term contracts, inventory hedging\u003c\/li\u003e\n\n\u003c\/pmanaging\u003e\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Global Direct Commercial Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmphastar’s sales are heavily US-centric: about 88% of 2024 revenue of $515 million came from the United States, leaving limited direct commercial reach abroad.\u003c\/p\u003e\n\u003cp\u003eBuilding local sales teams or using distributors raises SG\u0026amp;A and cuts margins; entering 10 new markets could require $20–50 million upfront per region in typical pharma rollouts.\u003c\/p\u003e\n\u003cp\u003eThat US concentration heightens exposure to federal reimbursement changes and FDA shifts, which could materially affect earnings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue $515M; ~88% US\u003c\/li\u003e\n\u003cli\u003eInternational footprint limited; reliance on partners\u003c\/li\u003e\n\u003cli\u003eHigh upfront market entry cost: $20–50M\/region est.\u003c\/li\u003e\n\u003cli\u003eConcentrated regulatory risk from US policy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh US concentration, product risk and margin squeeze threaten earnings stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh product concentration: ~40% of 2024 revenue from Primatene Mist and Baqsimi; US sales ~88% of $515M. Regulatory risk: history of FDA CRLs, 12‑month NDA delay in 2023, analysts in 2025 model ±15% EPS volatility. Margin pressure: 2024 adjusted operating margin ~12%; raw-material inflation cut gross margin ~1.8 ppt; R\u0026amp;D ~11% ($~60M) reduces near-term profit.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$515M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS %\u003c\/td\u003e\n\u003ctd\u003e~88%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct concentration\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. op. margin\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e~11% ($60M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGM drag\u003c\/td\u003e\n\u003ctd\u003e−1.8 ppt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAmphastar Pharmaceuticals SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Amphastar Pharmaceuticals SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable version with detailed strengths, weaknesses, opportunities, and threats for strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752817406329,"sku":"amphastar-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/amphastar-swot-analysis.png?v=1772245947","url":"https:\/\/matrixbcg.com\/products\/amphastar-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}